Coronary/Structural Heart

U.S. FDA Approves CytoSorbents to Initiate U.S. STAR-T Trial For Ticagrelor Removal During Cardiothoracic Surgery

MONMOUTH JUNCTION, N.J., April 19, 2021 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a critical care leader whose flagship E.U. approved CytoSorb® blood purification technology is intended to treat deadly conditions in critically-ill and cardiac surgery patients, announces that the U.S. Food and Drug Administration (FDA) has granted conditional approval of its investigational device exemption (IDE) application for […]

Windtree Therapeutics Announces New Istaroxime Expedited Review Filing of Patent

Company Continues to Leverage Data to Strengthen the Istaroxime Patent Estate WARRINGTON, Pa., April 19, 2021 /PRNewswire/ — Windtree Therapeutics, Inc. (NasdaqCM: WINT) (“Windtree” or the “Company”), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced it has filed a Track One […]

Vaica to Offer Anticoagulation Medication Adherence & Monitoring solution

TEL AVIV, Israel, April 19, 2021 /PRNewswire/ — Vaica™ Medical, an innovation leading provider in medication adherence and remote patient management (RPM) is announcing its anti-coagulation (blood clotting) remote management solution. The need to maintain an optimal blood viscosity levels is pertinent for at-risk patients with Thrombotic Predisposition (hypercoagulable states), heart rhythm disorders, […]

Neovasc Comments on EuroIntervention Article

VANCOUVER and MINNEAPOLIS, April 19, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that the journal EuroIntervention has published an article entitled, “Coronary Sinus Reducer Implantation Results in Improved Oxygen Kinetics at Cardiopulmonary Exercise Test in Patients with Refractory Angina.” The article, authored by Carlo Zivelonghi, M.D., Antwerp […]

LivaNova Achieves Clinical Milestone in Heart Failure Program

300th patient randomized in ANTHEM-HFrEF pivotal study LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it has randomized the 300th patient in the Autonomic Regulation Therapy to Enhance Myocardial Function and Reduce Progression of Heart Failure With Reduced Ejection Fraction (ANTHEM-HFrEF) Pivotal Study, which was approved by the U.S. Food and Drug Administration (FDA) […]

Elucid Presents Results of the EVAPORATE Study at ESC Preventive Cardiology 2021 Late Breakers

Elucid Software Quantifies Plaque Morphology to Enable Better Assessment of IPE Treatment Effects BOSTON–(BUSINESS WIRE)–Elucid, a medical technology company developing AI software for physicians to optimize the treatment of patients with known or suspected vascular disease, announced that first author and Elucid founder Andrew Buckler presented findings today from the […]

Neovasc Provides Tiara TA Update

VANCOUVER and MINNEAPOLIS, April 16, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), today announced that the Tiara Transapical system (“Tiara TA”) will be unable to receive a European CE mark under the current Medical Device Directive regulations (“MDD”) ending on May 26, 2021. The Company is […]

Seigla® Medical Receives CE Mark for LiquID™ Guide Catheter Extension

MINNEAPOLIS, April 16, 2021 /PRNewswire/ — Seigla Medical, Inc., announced conformité européenne (CE) Mark for the company’s LiquID™ Guide Catheter Extension for use in coronary and peripheral vasculature interventions. Guide catheter extensions are a crucial tool used by cardiologists worldwide to assist in the delivery of stents and other interventional devices. In addition, […]

Cardionomic Announces First Patients Enrolled in CPNS Pilot Study

Study evaluates safety and performance of endovascular pulmonary neuromodulation in ADHF MINNEAPOLIS, April 15, 2021 /PRNewswire/ — Cardionomic, Inc., a Minneapolis medical device company, is pleased to announce initial enrollment in their Cardionomic Pulmonary Neuromodulation System (CPNS) Pilot Study. The study will evaluate the safety and performance of the CPNS in patients suffering from Acute […]

Silence Therapeutics Announces Publication in Cardiovascular Research Highlighting the Emerging Potential of RNA Therapeutics in Preventing Lipoprotein(a)-Mediated Cardiovascular Disease

Silence Therapeutics Announces Publication in Cardiovascular Research Highlighting the Emerging Potential of RNA Therapeutics in Preventing Lipoprotein(a)-Mediated Cardiovascular Disease       –High Lipoprotein(a) is a genetically determined cardiovascular risk factor affecting around 20% of the world’s population  15 April 2021 LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN (“Silence” or “the Company”), […]